Figure 1.
Flowchart for the inclusion of valproate-treated patients with epilepsy.
Table 1.
Clinical characteristics of patients with epilepsy who received valproate treatment.
Table 2.
Logistic regression model for metabolic syndrome and its components in patients treated with valproate compared to control subjects.
Table 3.
Characteristics of subjects receiving valproate monotherapy with and without metabolic syndrome.
Table 4.
Anthropometric and laboratory data in the patients and control subjects.
Figure 2.
Receiver operating characteristic (ROC) curves of the homeostasis model assessment-estimated insulin resistance (HOMA-IR) and body mass index (BMI) values in control subjects.
BMI and HOMA-IR curves were obtained by logistic regression to determine the probability of metabolic syndrome (MS) in control subjects. AUC, area under the curve.
Figure 3.
Receiver operating characteristic (ROC) curves of the homeostasis model assessment-estimated insulin resistance (HOMA-IR) and body mass index (BMI) values in valproate (VPA)-treated patients.
BMI and HOMA-IR curves were obtained by logistic regression to determine the probability of metabolic syndrome (MS) in patients treated with VPA. AUC, area under the curve.